×

Research and Markets: Key Findings from Treatment Algorithms: Type 2 Diabetes

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/dsplpc/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Type 2 Diabetes" to their offering.

For more than a decade, U.S. physicians relied heavily upon metformin and the sulfonylureas for the treatment of type 2 diabetes prior to third-line initiation of insulin. However, in recent years, several new drug classes have emerged to challenge these generic agents, and these novel drug classes now contribute significantly to the overall type 2 diabetes market, which topped $20 billion in 2009.

Branded agents vying for space in second-line treatment include the DPP-IV inhibitors Januvia (Merck's sitagliptin) and Onglyza (Bristol-Myers Squibb/AstraZeneca's saxagliptin), the PPAR-gamma agonist Actos (Takeda's pioglitazone), the GLP-1 analogues Byetta (Amylin/Eli Lilly's exenatide) and Victoza (Novo Nordisk's liraglutide), and the insulin analogues Lantus (Sanofi-Aventis's insulin glargine) and Levemir (Novo Nordisk's insulin detemir).

This report provides an insight into which of these agents is winning the greatest patient share in newly diagnosed patients as well as recently treated patients, and how newer agents such as Onglyza and Victoza are faring against their more-established competitors. Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

Key Topics Covered:

1. Background

- Publication Update

- Report Contents and Features

- Current Practice Guidelines

- Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

- Executive Summary

- Graphical Views

3. Key Findings for Recently Treated Patients

- Executive Summary

- Graphical Views

4. Key Findings by Product

- Januvia

- Onglyza

- Byetta

- Victoza

- Actos

- Lantus

- Levemir

5. Appendix: Methodology

For more information visit http://www.researchandmarkets.com/research/dsplpc/key_findings_from

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets